Genomma Lab Internacional SAB de CV Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
July 26, 2016
Share
Genomma Lab Internacional SAB de CV announced consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported net sales of MXN 2,838.3 million compared with MXN 2,974.7 million for the same period a year ago. EBITDA was MXN 526.8 million compared with MXN 596.2 million for the same period a year ago. Operating income was MXN 504.8 million compared with MXN 567.7 million for the same period a year ago. Net income of majority shareholders was MXN 355.3 million compared with MXN 358.8 million for the same period a year ago. Net income amounted to MXN 369.4 million in the second quarter of 2016, compared to MXN 388.0 million during the second quarter of 2015. EBITDA was MXN 526.8 million compared to MXN 596.2 million a year ago. Adjusted EBITDA was MXN 542.9 million compared to MXN 602.2 million a year ago. Net cash from operating activities was MXN 424.751 million purchase of property, plant & equipment was MXN 9.5 million. Income before income taxes was MXN 535.137 million compared with MXN 519.300 million for the same period a year ago. Income from continuing operations was MXN 369.435 million compared with MXN 351.575 million for the same period a year ago.
For the six months, the company reported net sales of MXN 5,688.9 million compared with MXN 5,743.2 million for the same period a year ago. EBITDA was MXN 1,021.8 million compared with MXN 1,036.5 million for the same period a year ago. Operating income was MXN 971.3 million compared with MXN 979.2 million for the same period a year ago. Net income of majority shareholders was MXN 714.0 million compared with MXN 496.8 million for the same period a year ago. EBITDA was MXN 1,021.847 million compared to MXN 1,036.514 million a year ago. Income before income taxes was MXN 1,083.263 million compared with MXN 759.976 million for the same period a year ago. Income from continuing operations was MXN 795.667 million compared with MXN 477.317 million for the same period a year ago. Net cash generated in operating activities was MXN 1,178.895 million. Investment in fixed assets was MXN 10.256 million compared to MXN 37.320 million a year ago.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
